A2VDU3
SS
Gene name |
MAP3K7 |
Protein name |
Mitogen-activated protein kinase kinase kinase 7 |
Names |
EC 2.7.11.25 |
Species |
Bos taurus (Bovine) |
KEGG Pathway |
bta:529146 |
EC number |
2.7.11.25: Protein-serine/threonine kinases |
Protein Class |
|
Descriptions
TAK1 is a serine/threonine kinase involved in MAP kinase signal transduction pathway. Removal of N-terminal 22 amino acids recovers TAK1 activity.
Autoinhibitory domains (AIDs)
Target domain |
36-291 (Protein kinase domain) |
Relief mechanism |
Ligand binding, Partner binding |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for A2VDU3
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-A2VDU3-F1 | Predicted | AlphaFoldDB |
No variants for A2VDU3
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| No variants for A2VDU3 | |||||
No associated diseases with A2VDU3
19 regional properties for A2VDU3
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | Kringle | 462 - 545 | IPR000001 |
| domain | Protein kinase domain | 655 - 934 | IPR000719 |
| domain | Serine-threonine/tyrosine-protein kinase, catalytic domain | 656 - 934 | IPR001245 |
| domain | Immunoglobulin subtype 2 | 40 - 106 | IPR003598-1 |
| domain | Immunoglobulin subtype 2 | 133 - 197 | IPR003598-2 |
| domain | Immunoglobulin subtype 2 | 224 - 289 | IPR003598-3 |
| domain | Immunoglobulin subtype | 34 - 118 | IPR003599-1 |
| domain | Immunoglobulin subtype | 127 - 209 | IPR003599-2 |
| domain | Immunoglobulin subtype | 218 - 304 | IPR003599-3 |
| domain | Immunoglobulin-like domain | 28 - 116 | IPR007110-1 |
| domain | Immunoglobulin-like domain | 121 - 207 | IPR007110-2 |
| domain | Immunoglobulin-like domain | 212 - 302 | IPR007110-3 |
| active_site | Tyrosine-protein kinase, active site | 799 - 811 | IPR008266 |
| domain | Immunoglobulin I-set | 29 - 112 | IPR013098-1 |
| domain | Immunoglobulin I-set | 121 - 201 | IPR013098-2 |
| binding_site | Protein kinase, ATP binding site | 661 - 689 | IPR017441 |
| conserved_site | Kringle, conserved site | 513 - 526 | IPR018056 |
| domain | Frizzled domain | 312 - 451 | IPR020067 |
| domain | Tyrosine-protein kinase, catalytic domain | 655 - 934 | IPR020635 |
Functions
| Description | ||
|---|---|---|
| EC Number | 2.7.11.25 | Protein-serine/threonine kinases |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
2 GO annotations of cellular component
| Name | Definition |
|---|---|
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
4 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| magnesium ion binding | Binding to a magnesium (Mg) ion. |
| MAP kinase kinase kinase activity | Catalysis of the phosphorylation and activation of a MAP kinase kinase; each MAP kinase kinase can be phosphorylated by any of several MAP kinase kinase kinases. |
| protein serine kinase activity | Catalysis of the reactions |
6 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| I-kappaB phosphorylation | The process of introducing a phosphate group into an inhibitor of kappa B (I-kappaB) protein. Phosphorylation of I-kappaB targets I-kappaB for ubiquitination and proteasomal degradation, thus releasing bound NF-kappaB dimers, which can translocate to the nucleus to bind DNA and regulate transcription. |
| immune response | Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. |
| JNK cascade | An intracellular protein kinase cascade containing at least a JNK (a MAPK), a JNKK (a MAPKK) and a JUN3K (a MAP3K). The cascade can also contain an additional tier |
| positive regulation of canonical NF-kappaB signal transduction | Any process that activates or increases the frequency, rate or extent of I-kappaB kinase/NF-kappaB signaling. |
| positive regulation of JUN kinase activity | Any process that activates or increases the frequency, rate or extent of JUN kinase activity. |
37 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q4TVR5 | DSTYK | Dual serine/threonine and tyrosine protein kinase | Bos taurus (Bovine) | PR |
| Q3SZJ2 | RIPK2 | Receptor-interacting serine/threonine-protein kinase 2 | Bos taurus (Bovine) | PR |
| Q6XUX0 | DSTYK | Dual serine/threonine and tyrosine protein kinase | Gallus gallus (Chicken) | PR |
| Q95UN8 | slpr | Mitogen-activated protein kinase kinase kinase | Drosophila melanogaster (Fruit fly) | EV |
| P83104 | Takl1 | Putative mitogen-activated protein kinase kinase kinase 7-like | Drosophila melanogaster (Fruit fly) | PR |
| O43353 | RIPK2 | Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (Human) | PR |
| Q02779 | MAP3K10 | Mitogen-activated protein kinase kinase kinase 10 | Homo sapiens (Human) | SS |
| Q8NB16 | MLKL | Mixed lineage kinase domain-like protein | Homo sapiens (Human) | EV |
| Q16584 | MAP3K11 | Mitogen-activated protein kinase kinase kinase 11 | Homo sapiens (Human) | EV |
| P00540 | MOS | Proto-oncogene serine/threonine-protein kinase mos | Homo sapiens (Human) | PR |
| Q5TCX8 | MAP3K21 | Mitogen-activated protein kinase kinase kinase 21 | Homo sapiens (Human) | PR |
| Q6XUX3 | DSTYK | Dual serine/threonine and tyrosine protein kinase | Homo sapiens (Human) | PR |
| Q9NYL2 | MAP3K20 | Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (Human) | PR |
| Q38SD2 | LRRK1 | Leucine-rich repeat serine/threonine-protein kinase 1 | Homo sapiens (Human) | EV |
| P80192 | MAP3K9 | Mitogen-activated protein kinase kinase kinase 9 | Homo sapiens (Human) | SS |
| O43318 | MAP3K7 | Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens (Human) | SS |
| Q80XI6 | Map3k11 | Mitogen-activated protein kinase kinase kinase 11 | Mus musculus (Mouse) | PR |
| Q8VDG6 | Map3k21 | Mitogen-activated protein kinase kinase kinase 21 | Mus musculus (Mouse) | PR |
| P58801 | Ripk2 | Receptor-interacting serine/threonine-protein kinase 2 | Mus musculus (Mouse) | PR |
| Q3U1V8 | Map3k9 | Mitogen-activated protein kinase kinase kinase 9 | Mus musculus (Mouse) | SS |
| Q9D2Y4 | Mlkl | Mixed lineage kinase domain-like protein | Mus musculus (Mouse) | SS |
| Q9ESL4 | Map3k20 | Mitogen-activated protein kinase kinase kinase 20 | Mus musculus (Mouse) | PR |
| P00536 | Mos | Proto-oncogene serine/threonine-protein kinase mos | Mus musculus (Mouse) | PR |
| Q66L42 | Map3k10 | Mitogen-activated protein kinase kinase kinase 10 | Mus musculus (Mouse) | SS |
| Q62073 | Map3k7 | Mitogen-activated protein kinase kinase kinase 7 | Mus musculus (Mouse) | EV |
| Q66HA1 | Map3k11 | Mitogen-activated protein kinase kinase kinase 11 | Rattus norvegicus (Rat) | PR |
| D3ZG83 | Map3k10 | Mitogen-activated protein kinase kinase kinase 10 | Rattus norvegicus (Rat) | SS |
| P00539 | Mos | Proto-oncogene serine/threonine-protein kinase mos | Rattus norvegicus (Rat) | PR |
| P0C8E4 | Map3k7 | Mitogen-activated protein kinase kinase kinase 7 | Rattus norvegicus (Rat) | SS |
| Q9TZM3 | lrk-1 | Leucine-rich repeat serine/threonine-protein kinase 1 | Caenorhabditis elegans | SS |
| Q9FPR3 | EDR1 | Serine/threonine-protein kinase EDR1 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q2MHE4 | HT1 | Serine/threonine/tyrosine-protein kinase HT1 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| O22558 | STY8 | Serine/threonine-protein kinase STY8 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q8RWL6 | STY17 | Serine/threonine-protein kinase STY17 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| F4JTP5 | STY46 | Serine/threonine-protein kinase STY46 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q05609 | CTR1 | Serine/threonine-protein kinase CTR1 | Arabidopsis thaliana (Mouse-ear cress) | PR |
| Q67E00 | dstyk | Dual serine/threonine and tyrosine protein kinase | Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSTASAASSS | SSSSAGEMIE | APSQVLNFEE | IDYKEIEVEE | VVGRGAFGVV | CKAKWRAKDV |
| 70 | 80 | 90 | 100 | 110 | 120 |
| AIKQIESESE | RKAFIVELRQ | LSRVNHPNIV | KLYGACLNPV | CLVMEYAEGG | SLYNVLHGAE |
| 130 | 140 | 150 | 160 | 170 | 180 |
| PLPYYTAAHA | MSWCLQCSQG | VAYLHSMQPK | ALIHRDLKPP | NLLLVAGGTV | LKICDFGTAC |
| 190 | 200 | 210 | 220 | 230 | 240 |
| DIQTHMTNNK | GSAAWMAPEV | FEGSNYSEKC | DVFSWGIILW | EVITRRKPFD | EIGGPAFRIM |
| 250 | 260 | 270 | 280 | 290 | 300 |
| WAVHNGTRPP | LIKNLPKPIE | SLMTRCWSKD | PSQRPSMEEI | VKIMTHLMRY | FPGADEPLQY |
| 310 | 320 | 330 | 340 | 350 | 360 |
| PCQYSDEGQS | NSATSTGSFM | DITSTNTSNK | SDTNMEQVPA | TNDTIKRLES | KLLKNQAKQQ |
| 370 | 380 | 390 | 400 | 410 | 420 |
| SESGRLSLGA | SRGSSVESLP | PTSEGKRMSA | DMSEIEARIA | ATTGNGQPRR | RSIQDLTVTG |
| 430 | 440 | 450 | 460 | 470 | 480 |
| TDPGQVSSRS | SSPSVRMITT | SGPTSEKPAR | SHPWTPDDST | DTNGSDNSIP | MAYLTLDHQL |
| 490 | 500 | 510 | 520 | 530 | 540 |
| QPLAPCPNSK | ESMAVFEQHC | KMAQEYMKVQ | TEIALLLQRK | QELVAELDQD | EKDQQNTSRL |
| 550 | 560 | 570 | |||
| VQEHKKLLDE | NKSLSTYYQQ | CKKQLEVIRS | QQQKRQGTS |